logo
Plus   Neg
Share
Email

Boston Scientific To Acquire Cryterion Medical

Boston Scientific Corp. (BSX) said that it agreed to acquire Cryterion Medical, Inc., a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation or AF.

Boston Scientific has been an investor in Cryterion since its inception in 2016 and the transaction price for the approximately 65 percent remaining stake not already owned by Boston Scientific consists of $202 million in up-front cash.

Boston Scientific expects the transaction to be immaterial on an adjusted earnings per share basis through 2020, and accretive thereafter. On a GAAP basis for 2019 and subsequent years, the transaction is expected to be less accretive, or more dilutive as the case may be, due to amortization expense and acquisition-related net charges. For 2018 on a GAAP basis, the transaction is expected to be accretive due to a one-time gain on prior investment.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A US appeals court ruled against an order President Donald Trump issued last month that denies asylum pleas of migrants who crossed the southern border illegally. Two members of the three-judge bench of the 9th US Circuit Court of Appeals said late Friday that the ban is inconsistent with an existing US law, and attempts to over-run Congress. A presidential order signed on November 9 says that t A collection of the popular stories from the cryptocurrency and blockchain space this week. After fluctuating early in the session, stocks moved sharply lower over the course of the trading day on Friday. The major averages showed a substantial move back to the downside following the rebound from early weakness seen in the previous session.
Follow RTT